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INTRODUCTION
The heat shock proteins (HSPs) are highly conserved and
ubiquitous molecules with an essential defense mechanism for
protecting cells from various environmental damages (1, 2).
The HSPs are inducible in response to various physiologically
or pathologically stressful conditions, including carcinogenesis
(1-4). The functions of the HSPs in the tumorigenesis have
been implicated in the regulation of cell cycle progression and
apoptosis (5, 6), in multidrug resistance (7), and as a modu-
lator of p53 function (8). HSPs have been classified into six
major families and designated nomenclature according to their
approximate molecular weight: HSP100, HSP90, HSP70,
HSP60, HSP40, and small HSPs including HSP27 (9-12).
Based on their regulatory roles in cell apoptosis, HSPs are di-
vided into two groups: pro-apoptotic and anti-apoptotic HSPs
(6). Both HSP70 and HSP27 are potent anti-apoptotic HSPs,
and their overexpression allows cells to survive in the variable
conditions (4, 6). Thus, they may participate in carcinogenesis
and modulate tumor cell proliferation and survival through
the regulation of apoptotic pathways (4-6, 13, 14). Until now,
the exact mechanism of apoptosis-related HSP functions has
not been clarified, however the chaperone function of HSP70
was clearly established in the regulation of pro-apoptotic p53
protein (15). 
There were several reports about HSP70 expression in mali-
gnant tumors, such as breast cancer (7), lung cancer (16), oral
squamous cell carcinoma (17), prostate cancer (18), and car-
cinoma of the uterine cervix (19). The majority of the pub-
lished results demonstrated HSP70 overexpression correlated
with poor prognosis and resistance to therapy (7, 17, 18). In-
creased levels of HSP27 were detected in a number of cancers,
especially hormone-sensitive neoplasm (20, 21). Previous stud-
ies about the clinical implications of HSP27 showed different
results according to tumor types (20-23).
Hepatocellular carcinoma (HCC) is one of the world’s most
common malignancies, especially in Asia and southern Africa.
Most HCCs are associated with chronic liver diseases result-
ed from hepatitis B or C viral infection, and the processes of
chronic inflammation and fibrosis act as a stressful condition.
HSPs induced in response to this stress condition may con-
tribute to hepatocarcinogenesis. Until now there have been
a few comprehensive studies of the expression of HSP70 or
HSP27 in HCC (22-24), however its prognostic relevance re-
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Expressions of HSP70 and HSP27 in Hepatocellular Carcinoma
The heat shock proteins (HSPs) are ubiquitous molecules induced in cells exposed
to various stress conditions, including carcinogenesis. The HSP70 and HSP27 among
HSPs are of special relevance in human cancer inhibiting apoptosis. The aim of this
study is to investigate the expressions of HSP70 and HSP27 in hepatocellular car-
cinoma (HCC) in association to tumor cell proliferation and apoptosis. We exam-
ined the expressions of HSP70 and HSP27 by immunohistochemical staining in 71
cases of HCC, and then related their expressions to clinicopathologic parameters
and expressions of p53, Ki-67 and Apotag. HSP70 and HSP27 were frequently sta-
ined in the cytoplasm and nuclei of tumor cells, but not in the non-neoplastic hepa-
tocytes. Immunoreactivities of HSP70 and HSP27 were observed in 56.3% and
61.9% of HCCs, respectively. HSP70 immunoreactivity correlated with high Ki-67
labeling indices (LIs) (p=0.0159), large tumor size (p=0.0129), presence of portal
vein invasion (p=0.0231), and high tumor stage (p=0.0392). HSP27 immunoreactivity
significantly related with the subgroup of HBV-associated HCCs (p=0.0003), but
not with the others. Both HSP70 and HSP27 immunoreactivities showed no relation
to Apotag LIs or p53 immunoreactivity. In conclusion, expressions of HSP70 and
HSP27 may play an important role in hepatocarcinogenesis, and especially HSP70
showed a close relationship to the pathological parameters associated with tumor
progression and high Ki-67 LIs. Our results could be additional evidence that HSP70
expressions can contribute to not only hepatocarcinogenesis but also tumor progres-
sion by promoting tumor cell proliferation.
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mains controversial. In addition, there have been few studies
on HSP expressions in association with tumor cell proliferation
or apoptosis in HCCs. The purpose of this study is to investi-
gate the expressions of HSP70 and HSP27 in HCC in associa-
tion to tumor cell proliferation and apoptosis. Therefore we
examined the expressions of HSP70 and HSP27 by immuno-
histochemical staining in 71 cases of HCC, and then related
their expressions to clinicopathologic parameters and expres-
sions of p53, Ki-67 and Apotag.
MATERIALS AND METHODS
Clinicopathologic findings
Specimens used in this study consisted of 71 cases of sur-
gically resected HCC. Seventy-one patients (65 male; 6 female,
with a median age of 54.7 yr) who have HCC underwent liver
resection between 1996 and 2003 in the Inje University Seoul
Paik Hospital. The clinical data including the status of hep-
atitis markers were documented for all patients. There were
52 cases with HBV infection (positive serum HbsAg), 7 with
HCV infection (positive anti-HCV), and 12 with no infection.
All HCC specimens were comprised of both tumor and adja-
cent non-tumorous tissue. Sections from formalin-fixed, paraf-
fin-embedded tissues were used for the immunohistochemical
detection of HSP70, HSP27, p53, Ki-67, and Apotag. We
compared their expressions with the following pathological
characteristics: histologic grade, tumor size, portal vein inva-
sion, intrahepatic metastasis, and tumor stage. HCC tissues
were classified based on the degree of differentiation into well
and poor according to the criteria of Edmondson and Steiner
(25) with some modification; well (grades 1 & 2) (n=20) and
poor (grades 3 & 4) (n=51). Tumor size was recorded as the
greatest dimension of each specimen, and was classified based
on the criteria of Yumoto et al. (26); small (tumor mass <3 cm)
(n=24) and large (tumor mass ≥3 cm) (n=47). Tumor staging
was determined in accordance with the TNM classification
system of UICC (1997) (27), and cases were classified into two
groups; low (T1 & T2) (n=21) and high (T3 & T4) (n=50).
Immunohistochemical staining
Immunostaining was performed by the conventional avi-
din-biotin complex (ABC) method. Commercially available
monoclonal antibodies for HSP70 (1:50, Neomarker, Fremont,
CA, U.S.A.), HSP27 (1:50, Neomarker), p53 (1:200, DAKO,
Carpinteria, CA, U.S.A.), and Ki-67 (1:100, DAKO) were
used. For antigen retrieval, the sections were immersed in a
citrate buffer and processed in a microwave oven at 95℃ for
10 min. They were developed in a substrate solution of 0.01%
3,3′ -diaminobenzidine tetrachloride (DAB) (DAKO) and
counterstained with Meyer’s hematoxylin. As positive controls
for HSP70 and HSP27, p53, and Ki-67, breast carcinoma,
colon carcinoma, and tonsilar tissue were used, respectively.
Nonimmune mouse serum was used as a substitute for the
primary negative controls. Apoptosis was measured by Apo-
tag immunostaining in paraffin embedded sections using the
Biogenex ISH detection kit (SH-1009-06; San Ramon, CA,
U.S.A.) according to the manufacturer’s instructions. In brief,
sections were deparaffinized with xylene, pretreated with pro-
teinase K to improve the exposure of DNA by digesting DNA
binding protein, rinsed with PBS, and incubated in a reaction
mixture containing terminal transferase and digoxigenin
dUTP at 37℃ for 1 hr. The specimens were then washed,
followed by the addition of antidigoxigenin peroxidase anti-
body coupled with horseradish peroxidase, and the tissues
were incubated for 30 min at room temperature. Following
rinsing with PBS, DAB was added for 10 min. Sections of
lymph nodes were used as positive control for apoptosis.
Interpretation of immunohistochemical results
For HSP70 and HSP27, any staining either in the cyto-
plasms or nuclei was regarded as positive. The distribution of
positive staining for HSP70 and HSP27 was semiquatitative-
ly assessed by the percentage of positive cells and the cases
were classified into three groups according to the proportion
of positive tumor cells: 2+ (over 50%), 1+ (between 10% and
50%), and negative (less than 10%) (16). Given the reported
correlation of p53 gene mutations with the accumulation of
p53 protein in ≥10 percent tumor cell nuclei (28), the tu-
mors were regarded as p53-positive when at least 10 percent
of the tumor cells showed nuclear p53 protein accumulation.
For the assessment of the expressions of Ki-67 and Apotag,
the labeling index (LI) for these antigens (positive nuclei/total
number of counted nuclei) was determined by a random eval-
uation of 1,000 tumor cells.
Statistical analysis
The immunoreactivities of HSP70 and HSP27 in relation
to the pathological parameters including p53 immunoreactivi-
ty were examined with the chi-square test. To analyze the sta-
tistical differences of Ki-67 LI and Apotag LI according to the
immunoreactivities of HSP70 and HSP27, the Kruskal-Wallis
test was used. The correlation between Ki-67 LI and Apotag
LI was analyzed by Spearman’s correlation test. Significance
was defined as p<0.05. All statistical analyses were performed
using SPSS software (version 10.0, SPSS INC., Chicago, IL).
RESULTS
Immunoreactivities of HSP70 and HSP27 
In non-neoplastic liver tissue, HSP70 and HSP27 were not
significantly expressed in hepatocytes. We detected a few scat-tered HSP70-positive hepatocytes with a weak cytoplasmic
staining. In contrast, the bile duct epithelium is constantly
positive for HSP70 with a strong intensity (Fig. 1A). In HCCs,
HSP70 immunoreactivity was seen in 40 cases (56.3%) (1+,
23 cases; 2+, 17 cases), and HSP27 was stained in 44 cases
(61.9%) (1+, 27 cases; 2+, 17 cases). HSP70 immunoreac-
tivity was observed in both the nucleus and cytoplasm with
a finely granular pattern (Fig. 1B). HSP27 immunoreactivi-
ty was predominantly cytoplasmic (Fig. 1C), and in 20 cases,
combined nuclear staining was also detected in variable num-
bers of neoplastic cells (Fig. 1D).
Correlation between HSP immunoreactivity and clinico-
pathologic findings
To understand the implications of the HSP expression in
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Fig. 1. Representative photographs of immunohistochemical stainings of HSP70, HSP27, Ki-67, and Apotag. (A) Cytoplasmic staining of
HSP70 in non-neoplastic bile ductules as internal control (×100), (B) Nucleocytoplasmic staining of HSP70 in HCCs with fine granular pat-
tern (×200), (C) Strong cytoplasmic staining of HSP27 in HCC (×200), (D) Combined nuclear staining of HSP27 in HCC (×200), (E) High
Ki-67 expression in HCC (×200), (F) Apoptotic cells by the Apotag staining in HCC (×400).
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E Fhepatocarcinogenesis, the immunoreactivities of HSP70 and
HSP27 were analyzed for correlations with clinicopathologic
features. As shown in Table 1, HSP70 immunoreactivity sig-
nificantly correlated with large tumor size (p=0.0129), portal
vein invasion (p=0.0231), and high tumor stage (p=0.0392).
HSP27 immunoreactivity showed a high association with
HBV-associated HCC (p=0.0003), however there was no cor-
relation between any prognosis-related pathological parame-
ters and HSP27 immunoreactivity regardless of the presence
of nuclear expression.
p53 immunoreactivity, Ki-67 LI, and apotag LI in HCCs
p53 immunoreactivity was noted in 16 cases (22.5%) and
correlated with poor histologic grade (p=0.0114), high Ki-
67 LIs (p=0.0308), and high Apotag LIs (p=0.0177). Ki-67
LIs were ranged from 0.1 to 40 (mean 13.2±10.9) (Fig. 1E),
which significantly correlated with poor histologic grade
(p=0.0017), large tumor size (p=0.0047), and portal vein inva-
sion (p=0.0152). Tumor cells undergoing apoptosis displayed
specific brown staining in fragmented chromatin within the
nucleus, areas of chromatin condensation, as well as areas of
pyknosis and karyorrhexis. Apotag LIs were ranged from 0 to
15 (mean 2.52±2.13) (Fig. 1F) and correlated with poor his-
tologic grade (p=0.0007) and large tumor size (p=0.0136).
Furthermore, the Apotag LIs showed close correlation with
the Ki-67 LI (p=0.0001, Spearman’s correlation test). There
were significant relationships among the expressions of p53,
Ki-67, and Apotag, all of which correlated with HCC histolog-
ical grade (Table 1). 
Correlation between HSP immunoreactivities and p53
immunoreactivity, Ki-67 LI, and apotag LI in HCCs
p53 immunoreactivity did not correlate with the immuno-
reactivities of HSP70 or HSP27 in the overall group of HCCs.
We divided the group into two subgroups according to the
type of hepatitis virus. A significant relationship was observed
between immunoreactivities of HSP70 and p53 (p=0.0284)
in the HBV-associated HCC group (n=53), but not in the
HCV-associated HCC group (n=7). Ki-67 LIs were positively
correlated with HSP70 immunoreactivity (p=0.0159). Apotag
LIs showed no statistical significance with HSP immunore-
activities (Table 2).
DISCUSSION
Heat shock proteins have essential roles in protecting cells
from the potentially lethal effects of stress (1-4). Heat-shock
proteins have dual roles as a modifier to protein activities and
as a central regulator in both cell proliferation and apoptosis
(5, 6, 8, 15). Among them, HSP70 and HSP27 are often over-
expressed in cells of various cancers and have been suggested
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LI, labeling index; -, no expression; 1+, positive cell proportion between
10% and 50%; 2+, positive cell proportion over 50%; SD, standard devi-









Negative 8 8 2 14 2 2 17 1 9.41±8.12 3.22±2.84
Positive 23 15 15 13 25 15 38 15 14.43±11.43 2.3±1.93
p value 0.2538 0.0003 0.0951 0.2527 0.6612
HCV
Negative 28 20 16 22 27 15 49 15 13.59±11.15 2.44±1.99
Positive 3 3 1 5 0 2 6 1 8±6.86 3.53±3.7
p value 0.7535 0.0706 0.9412 0.3271 0.8998
Histologic grade
Well 12 4 4 12 5 3 20 0 4.75±4.4 1.42±1.79
Poor 19 19 13 15 22 14 35 16 16.47±11.42 2.95±2.12
p value 0.1758 0.0967 0.0114 0.0017 0.0007
Tumor size
≤3 cm 16 6 2 8 12 4 20 4 7.63±7.61 1.78±1.98
>3 cm 15 17 15 19 15 13 35 12 16±11.7 2.89±2.24
p value 0.0129 0.3045 0.5854 0.0047 0.0136
PVTE
Absence 16 10 2 12 11 5 25 3 9.14±8.89 1.81±1.81
Presence15 13 15 15 16 12 30 13 15.45±11.43 2.98±2.39
p value 0.0231 0.6011 0.1024 0.0152 0.0670
IHM
Absence 18 19 12 17 17 15 37 12 12.57±10.25 2.67±2.29
Presence13 4 5 10 10 2 18 4 14.5±12.22 2.18±1.82
p value 0.1537 0.1450 0.7786 0.7450 0.6042
Tumor stage
Low 8 11 2 9 8 4 18 3 10.09±7.56 1.98±1.87
(T1+T2)
High 23 12 15 18 19 13 37 13 14.46±11.88 2.74±2.27
(T3+T4)
p value 0.0392 0.7861 0.4431 0.3515 0.3490
Table 1. Expressions of HSP70, HSP27, p53, Ki-67, and Apotag
in association with clinicopathologic parameters in HCCs 
Ki-67 LI
(mean±SD) - 1+ 2+
LI, labeling index; -, no expression; 1+, positive cell proportion between
10% and 50%; 2+, positive cell proportion over 50%; SD, standard devia-
tion.
HSP70
- 31 27 4 8.8710±8.866 1.915±1.84
1+ 23 15 8 14.3478±10.945 3.222±2.667
2+ 17 13 4 19.4118±9.585 2.676±1.875
p value 0.1626 0.0159 0.329
HSP27
- 27 22 5 10.22±8 2.752±2.48
1+ 27 20 7 15.77±12.757 2.439±1.911
2+ 17 13 4 12.59±11.114 2.282±1.985
p value 0.8037 0.286 0.743
Table 2. Expressions of HSP70 and HSP27 in association to









HSP70 HSP27 p53to contribute to tumorigenesis (3, 4). According to the results
of proteome analysis (29) or expression profiling using oligo-
nucleotide array (24) studied in HCC, HSP70 was introduced
as a useful HCC marker and may play an important role in
stepwise progression of hepatocarcinogenesis. In our study,
HSP70 immunoreactivity was specifically detected in tumor
cells and showed a close relationship to the pathologic param-
eters related to tumor progression, such as large tumor size,
portal vein invasion, and high tumor stage. In addition, a
positive correlation between HSP70 immunoreactivity and
Ki-67 LIs was confirmed, and Ki-67 LIs significantly corre-
lated with adverse prognostic factors as well. The roles of
HSP70 in promoting tumor cell proliferation were previous-
ly observed in the various types of carcinoma (16, 17, 19, 30),
but not in HCC. Recently, it has been shown that HSP70
antisense oligomers can specifically inhibit tumor cell prolifer-
ation by inducing apoptosis (17, 31); these results suggest that
anti-apoptotic functions of HSP70 may play an important role
in tumor cell proliferation and tumor progression in HSP70
over-expressed tumors like HCC. Even though we were not
able to demonstrate a relationship between apoptotic indices
(Apotag LIs) and HSP70 immunoreactivity in this series, our
results could be additional evidence that HSP70 expression
can contribute to not only hepatocarcinogenesis but also tu-
mor progression by promoting tumor cell proliferation.
Another plausible role for HSPs in tumorigenesis is as a
modifier of protein activities (3, 4). The tumor suppressor p53
protein, involved in the control of cell proliferation, represses
transcription by direct protein-protein interaction with the
promoter region of the human HSP70 gene (15, 32). Indeed,
HSP70-p53 complexes can be detected in extracts from hu-
man cancer tissues (33). Cui et al. (34) has reported that coim-
munoprecipitation of anti-HSP70 mAb and anti-p53 mAb
was shown in 3 out of 12 HCC tissues (25%). In the current
study, a statistically significant association between the immu-
noreactivities of HSP70 and p53 was not shown. However,
there was a tendency that the majority of cases showing p53
immunoreactivity (75%, 12 of 16 cases) also demonstrated
HSP70 immunoreactivity, and a significant association bet-
ween the immunoreactivities of HSP70 and p53 was found
in the HBV-associated HCC group. Besides HSP70, multi-
ple chaperone complexes including HSP90, HSP40, and p23
mediate the stabilization and cytoplasmic sequestration of
conformational mutant p53 or wild-type p53 (15). Therefore
studying the coordinated expression of HSPs with p53 pro-
tein may be helpful to understand the roles of HSPs in the
regulation of p53 function. 
King et al. (22) reported that HSP27 expression was related
to histologic grade and the survival of patients with HCC.
According to the results reported by Harimoto et al. (23),
HSP27 expression did not correlated with clinicopathologic
factor in the overall group of HCCs; however, it is noticeable
that HSP27 expression correlated significantly with the prog-
nosis, disease-free survival and overall survival in HBV-asso-
ciated group. In the present study, HSP27 immunoreactivity
was also detected specifically in tumor cells, and showed a
high relevance to HBV-associated HCCs, while we were not
able to find any correlation between HSP27 immunoreactiv-
ities and the other parameters examined. HSP27 has been re-
ported as one of the most up-regulated genes (over 4-folds)
performed cDNA microarray analysis on 588 cellular DNA
in HepG2 cell line stably expressing Hepatitis B viral X pro-
tein (HBX) (35). HBX is known as a transcription factor and
potential oncogene, and it is strongly implicated in the devel-
opment of hepatocellular carcinoma in chronic HBV-infected
patients (36). In this respect, the induction of HSP27 genes
by HBX could suggest an additional role for viral protein in
HBV-associated carcinogenesis. More comprehensive research
will be required to clarify the association between HBV-asso-
ciated HCC and HSP27 up-regulation.
In the current study, we found expressions of HSP70 and
HSP27 may play an important role in hepatocarcinogenesis,
and especially HSP70 can contribute tumor progression by
promoting tumor cell proliferation in HCC. HSP27 might
contribute to the hepatocarcinogenesis of the HBV-associat-
ed subgroup.
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